Shares of Wave Life Sciences (WVE) surged 53.4% on Tuesday after the company announced positive interim data from a mid-stage study evaluating its investigational candidate, WVE-N531, to treat boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping. WVE-N531, an exon skipping oligonucleotide, is currently being developed as a disease-modifying treatment for DMD indication in boys. The candidate enjoys the FDA's Orphan Drug and Rare Pediatric Disease designations in the United States ...